Drug intelligence / Profile preview

Bio-K+ (Bio-K+)

Development stage: Unknown
Lead developer: Kerry
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bio-K+ is a proprietary probiotic formulation consisting of three specific, patented strains of live bacteria: *Lactobacillus acidophilus* CL1285, *Lactobacillus casei* LBC80R, and *Lactobacillus rhamnosus* CLR2. Developed by Bio-K Plus International (now a part of Kerry Group), this product is extensively studied for its efficacy in gastrointestinal health, particularly in the prevention of antibiotic-associated diarrhea (AAD) and *Clostridioides difficile* infections (CDI). The mechanism of action involves the restoration of the intestinal microbiota balance, competitive exclusion of enteric pathogens, and the production of antimicrobial metabolites such as lactic acid. Bio-K+ is unique in its delivery system, which includes fermented liquid substrates and enteric-coated capsules designed to protect the bacteria from gastric acidity, ensuring high viability upon reaching the intestinal tract. It is widely used in clinical and hospital settings as a prophylactic intervention for patients undergoing intensive antibiotic therapy.

Brand names: Bio-K+Bio-K
Other names: Bio-K PlusLactobacillus acidophilus CL1285 + Lactobacillus casei LBC80R + Lactobacillus rhamnosus CLR2

Beyond the preview

Go deeper on Bio-K+ (Bio-K+).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bio-K+ (Bio-K+).

Explore the full profile